10:16 AM EST - Mind Cure Health Inc. : Provided an operational progress update on the strategic initiatives of its operating segments - MINDCURE Research and MINDCURE Technology. MINDCURE is currently on schedule and expects to have GLP supply available for research partners beginning in Q2 of 2022. MINDCURE has completed its draft research protocol for the use of MDMA and psychotherapy to treat female sexual hypoactive desire disorder, known as The Desire Project. The Company expects a pre-IND meeting with the FDA to be scheduled in the first quarter of 2022 and for its Phase 2 trial to begin by the third quarter of 2022. Further, site initiation and initial screening are planned for March 2022, with recruitment and enrollment to follow. MINDCURE confirms that it is preparing to ship ibogaine drug material to its pre-clinical research partner. The Company released the minimum viable product ("MVP") of its digital therapeutics (DTx) technology, iSTRYM, into partner clinics across North America in August. MINDCURE announced that it has exceeded its previously announced target and timeline of 10 clinics by the end of 2021. The Company has already partnered with 20 ketamine clinics in nine states in the US and three provinces in Canada and plans to expand to the broader mental health market in 2022. Mind Cure Health Inc.
shares C.MCUR are trading off 1.56 percent at $0.32.
